SEC Filing Summary: Supernus Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Supernus Pharmaceuticals, Inc. on November 7, 2014. The filing primarily serves to announce the issuance of a new patent and to reference the company's financial results for the quarter ended September 30, 2014, which were detailed in a press release issued on November 11, 2014.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this 8-K report.
Material Changes and Events
- Patent Grant: On November 7, 2014, the United States Patent and Trademark Office issued a fourth patent covering Trokendi XR, the company's novel once-daily extended-release topiramate product.
- Financial Results Announcement: The company announced financial results for the quarter ended September 30, 2014, via a press release dated November 11, 2014.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding plans, strategies, and intentions, which are subject to risks and uncertainties. The company explicitly disclaims any obligation to update these statements. Specific risks are referenced in Item 1A of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013. A conference call to discuss the financial results was scheduled for November 12, 2014.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q3 2014 revenue, net loss, and cash position figures.
- Verify the scope and expiration date of the fourth patent granted for Trokendi XR (Exhibit 99.2).
- Listen to the archived webcast of the November 12, 2014 conference call for management commentary on the financial results.
- Consult the 2013 Form 10-K for a detailed list of risk factors applicable to the company's operations.